An AI-developed drug appeared to make patients biologically younger in a clinical trial
Serving tech enthusiasts for over 25 years.
TechSpot means tech analysis and advice you can trust.
What just happened? As we all know, we're still waiting for the cancer cure people said AI would bring. However, an AI-generated drug has shown signs of a different breakthrough: slowing the aging process. There's a catch, naturally: changes in aging markers don't prove we'll soon be living to 150.
The experimental drug, rentosertib, comes from Insilico Medicine and was developed to treat idiopathic pulmonary fibrosis, a disease that progressively scars the lungs.
According to the company, AI helped identify its target, a protein called TNIK, and design the molecule that inhibits it.
Now, a study published September 7 in Nature Biotechnologyhas revisited data from a phase 2a trial involving 71 patients in China. The aging analysis covered 42 participants, with an average age of about 67, whose blood samples were...
Copyright of this story solely belongs to www.techspot.com. To see the full text click HERE
